BMX-IN-1
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
Product Specifications
CAS Number
[1431525-23-3]
Product Name Alternative
BMX kinase inhibitor
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
BMX Kinase; Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BMX-IN-1.html
Purity
99.04
Solubility
DMF : 10 mg/mL (ultrasonic) |DMSO : 8.33 mg/mL (ultrasonic)
Smiles
O=C1N(C2=C(C=C1)C=NC3=CC=C(C4=CC=C(NS(=O)(C)=O)C=C4)C=C32)C5=CC=C(C)C(NC(C=C)=O)=C5
Molecular Formula
C29H24N4O4S
Molecular Weight
524.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Feiyang Liu , et al. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem. Biol., DOI: 10.1021/cb4000629
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
ZBED1 (Zinc Finger BED Domain-containing Protein 1, Putative Ac-like Transposable Element, ALTE, dREF Homolog, DREF, KIAA0785, TRAMP) (MaxLight 490)